In Vitro Models for Improved Therapeutic Interventions in Atrial Fibrillation.

Area of Science:

• Cardiovascular Research
• Biomedical Engineering
• Pharmacology

Background:

• Atrial fibrillation (AF) is a prevalent cardiac arrhythmia causing significant health issues like heart failure and stroke.
• Current treatments for AF involve pharmacological and non-pharmacological strategies.
• Effective therapeutic development necessitates reliable preclinical models to test and optimize interventions.

Purpose of the Study:

• To review and compare existing preclinical models for studying atrial fibrillation.
• To provide guidance on selecting appropriate models based on research objectives.
• To highlight the advantages, applications, and limitations of diverse AF models.

Main Methods:

• Comprehensive literature review of preclinical models for atrial fibrillation.
• Categorization of models including in vitro, traditional animal models, organoids, and organs-on-a-chip.
• Analysis of model-specific features, benefits, and drawbacks.

Main Results:

• A spectrum of preclinical models exists, each offering unique insights into AF pathophysiology.
• Traditional models like animal studies and cell cultures have established roles.
• Emerging technologies such as organoids and organs-on-a-chip offer advanced, human-relevant platforms.

Conclusions:

• The choice of preclinical model is critical for successful AF research and therapeutic validation.
• Each model type presents distinct advantages and limitations that must be considered.
• Selecting the right model ensures accurate assessment and optimization of AF treatments.